Lacosamida

Resumen

Alternativas con registro en Colombia

• Lamotrigina · costo anual estimado $ 1.018.350
• Topiramato · costo anual estimado $ 1.247.205
• Levetiracetam · costo anual estimado $ 294.555
• Estiripentol
• Perampanel
• Brivaracetam · costo anual estimado $ 5.214.025
• Cannabidiol · costo anual estimado $ 6.562.700

Estudios clínicos principales

• VALUE: Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
  Fase 3 · 2015 · 239 participantes · UCB BIOSCIENCES, Inc. · NCT02408549
• SP0993: Trial Comparing the Efficacy and Safety of Lacosamide (LCM) to Carbamazepine Controlled-Release (CBZ-CR); Initial Monotherapy in Epilepsy; Subjects Aged 16 and
  Fase 3 · 2011 · 888 participantes · UCB BIOSCIENCES GmbH · NCT01243177 · PubMed 27889312 · PubMed 33200428
• A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures
  Fase 3 · 2012 · 548 participantes · UCB Pharma SA · NCT01710657 · PubMed 23859801
• Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures
  Fase 3 · 2013 · 473 participantes · UCB Pharma SA · NCT01832038 · PubMed 34246118

Enfermedades relacionadas

• Epilepsia y convulsiones

Fuentes

• Etiqueta FDA (DailyMed): LACOSAMIDE
• EMA: Lacosamide UCB
• EMA: Vimpat